Aimwell Partners Inc (AIMN)

$0.00 0.00 (-2.50%)
Market Cap 1,000.00
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 594,200
Avg Vol 478,284
Day's Range N/A - N/A
Shares Out 137,000.00
Stochastic %K 12%
Beta 1,428.35
Analysts Strong Buy
Price Target N/A

Company Profile

Lee Pharmaceuticals, Inc. provides personal care products in the United States. The company offers aloe vera products, antacids, cosmetics and douches, cough and cold products, depilatories and waxes, laxatives, lip balm products, men's personal care products, monticello drugs, oral care products, pain relievers, skin care products, tobacco accessories, topical ointments and creams, baby care products, and vitamins and nutritional products, as well as nasal sprays, lip conditioners, and over the...

Industry: Shell Companies
Sector: Financial Services
Phone: 307-278-1360
Address:
11 N Water Street, Mobile, United States
762user
762user Jul. 4 at 4:49 PM
$AIMN
0 · Reply
PrnceMichael
PrnceMichael Jul. 2 at 4:51 PM
$AIMN The right network. The right context. @AimwellBIO Observer connects serious healthcare professionals to trusted signals, curated intelligence, and a verified network built for the future of healthcare. Apply free. Stay in the network. http://aimwellbio.com/observer-signup $AIMN #pharma $PFE $JNJ $MEDI
0 · Reply
UltimateTrader_22
UltimateTrader_22 Jul. 2 at 12:02 PM
$AIMN Bullish on $AIMN Strong early demand for AimwellBio’s FHIN Founding Cohort as it fights AI hallucinations with verified, traceable intelligence. Expanding fast in healthcare AI!
0 · Reply
St0ckman691
St0ckman691 Jul. 2 at 11:49 AM
$AIMN solid news out yesterday! https://finance.yahoo.com/technology/ai/articles/aimwell-partners-inc-publishes-adversarial-124500904.html
0 · Reply
UltimateTrader_22
UltimateTrader_22 Jul. 1 at 6:00 PM
$AIMN Aimwell Partners (OTC:AIMN), parent of AimwellBio, published Adversarial Validation Standard v1, an open, versioned methodology for validating AI-generated biopharma intelligence. The eight-section framework covers source-trace architecture, four-agent audits, confidence scoring, hallucination containment, governance, and failure-mode correction. The Standard underpins AimwellBio's Federated Health Intelligence Network, defines verification requirements before AI outputs inform regulatory, clinical, and strategic decisions, and is offered via tiered platform access, including a 60-page reference for subscribers and a 25-page abridged public edition. https://www.stocktitan.net/news/AIMN/aimwell-partners-inc-publishes-the-adversarial-validation-standard-06oahhp8prko.html
0 · Reply
PrnceMichael
PrnceMichael Jul. 1 at 4:38 PM
$AIMN AimwellBio's live signal intelligence engine is now tracking 13 source streams in real time - FDA actions, drug recalls, clinical trials, patent filings, global outbreaks, and regulatory divergence. It's running right now. The only question is whether you're seeing what it sees. https://www.accessnewswire.com/newsroom/en/business-and-professional-services/while-you-were-in-that-meeting-14-signals-moved.-your-competitor-1164121 @AimwellBIO @AimwellPartners
0 · Reply
UltimateTrader_22
UltimateTrader_22 Jul. 1 at 2:02 PM
$AIMN News: Aimwell Partners Inc. Publishes the Adversarial Validation Standard, v1, an Open Methodology Framework for Verifying AI-Generated Biopharma Intelligence @AimwellBIO @AimwellPartners #NEWS https://accessnewswire.com/newsroom/en/business-and-professional-services/aimwell-partners-inc.-publishes-the-adversarial-validation-stand-1185060
0 · Reply
St0ckman691
St0ckman691 Jul. 1 at 1:35 PM
$AIMN News out! https://finance.yahoo.com/technology/ai/articles/aimwell-partners-inc-publishes-adversarial-124500904.html
0 · Reply
St0ckman691
St0ckman691 Jul. 1 at 11:57 AM
$AIMN nice bounce off the bottom yesterday, let's see if we can get a continuation today.
0 · Reply
PrnceMichael
PrnceMichael Jul. 1 at 11:43 AM
$AIMN @AimwellPartners enters the $100B+ RegTech market with the launch of AimwellBio. As healthcare becomes the fastest-growing vertical in regulatory tech, Aimwell is building the "trust layer" for AI in medicine. 🔹 Solving the 47% AI error rate in medical advice. 🔹 Targeting $140B in annual BioPharma intelligence spend. 🔹 Launching the Federated Health Intelligence Network (FHIN). Check out the full release: https://accessnewswire.com/newsroom/en/business-and-professional-services/aimwellbio-launches-the-system-that-catches-what-ai-gets-wrong-b-1157560 #Investing #StockMarket #OTC #AI #BioPharma $AIMN #AimwellBio
0 · Reply
Latest News on AIMN
No data available.
762user
762user Jul. 4 at 4:49 PM
$AIMN
0 · Reply
PrnceMichael
PrnceMichael Jul. 2 at 4:51 PM
$AIMN The right network. The right context. @AimwellBIO Observer connects serious healthcare professionals to trusted signals, curated intelligence, and a verified network built for the future of healthcare. Apply free. Stay in the network. http://aimwellbio.com/observer-signup $AIMN #pharma $PFE $JNJ $MEDI
0 · Reply
UltimateTrader_22
UltimateTrader_22 Jul. 2 at 12:02 PM
$AIMN Bullish on $AIMN Strong early demand for AimwellBio’s FHIN Founding Cohort as it fights AI hallucinations with verified, traceable intelligence. Expanding fast in healthcare AI!
0 · Reply
St0ckman691
St0ckman691 Jul. 2 at 11:49 AM
$AIMN solid news out yesterday! https://finance.yahoo.com/technology/ai/articles/aimwell-partners-inc-publishes-adversarial-124500904.html
0 · Reply
UltimateTrader_22
UltimateTrader_22 Jul. 1 at 6:00 PM
$AIMN Aimwell Partners (OTC:AIMN), parent of AimwellBio, published Adversarial Validation Standard v1, an open, versioned methodology for validating AI-generated biopharma intelligence. The eight-section framework covers source-trace architecture, four-agent audits, confidence scoring, hallucination containment, governance, and failure-mode correction. The Standard underpins AimwellBio's Federated Health Intelligence Network, defines verification requirements before AI outputs inform regulatory, clinical, and strategic decisions, and is offered via tiered platform access, including a 60-page reference for subscribers and a 25-page abridged public edition. https://www.stocktitan.net/news/AIMN/aimwell-partners-inc-publishes-the-adversarial-validation-standard-06oahhp8prko.html
0 · Reply
PrnceMichael
PrnceMichael Jul. 1 at 4:38 PM
$AIMN AimwellBio's live signal intelligence engine is now tracking 13 source streams in real time - FDA actions, drug recalls, clinical trials, patent filings, global outbreaks, and regulatory divergence. It's running right now. The only question is whether you're seeing what it sees. https://www.accessnewswire.com/newsroom/en/business-and-professional-services/while-you-were-in-that-meeting-14-signals-moved.-your-competitor-1164121 @AimwellBIO @AimwellPartners
0 · Reply
UltimateTrader_22
UltimateTrader_22 Jul. 1 at 2:02 PM
$AIMN News: Aimwell Partners Inc. Publishes the Adversarial Validation Standard, v1, an Open Methodology Framework for Verifying AI-Generated Biopharma Intelligence @AimwellBIO @AimwellPartners #NEWS https://accessnewswire.com/newsroom/en/business-and-professional-services/aimwell-partners-inc.-publishes-the-adversarial-validation-stand-1185060
0 · Reply
St0ckman691
St0ckman691 Jul. 1 at 1:35 PM
$AIMN News out! https://finance.yahoo.com/technology/ai/articles/aimwell-partners-inc-publishes-adversarial-124500904.html
0 · Reply
St0ckman691
St0ckman691 Jul. 1 at 11:57 AM
$AIMN nice bounce off the bottom yesterday, let's see if we can get a continuation today.
0 · Reply
PrnceMichael
PrnceMichael Jul. 1 at 11:43 AM
$AIMN @AimwellPartners enters the $100B+ RegTech market with the launch of AimwellBio. As healthcare becomes the fastest-growing vertical in regulatory tech, Aimwell is building the "trust layer" for AI in medicine. 🔹 Solving the 47% AI error rate in medical advice. 🔹 Targeting $140B in annual BioPharma intelligence spend. 🔹 Launching the Federated Health Intelligence Network (FHIN). Check out the full release: https://accessnewswire.com/newsroom/en/business-and-professional-services/aimwellbio-launches-the-system-that-catches-what-ai-gets-wrong-b-1157560 #Investing #StockMarket #OTC #AI #BioPharma $AIMN #AimwellBio
0 · Reply
UltimateTrader_22
UltimateTrader_22 Jun. 30 at 3:55 PM
$AIMN +40.00% Today. #Bullish New HOD On ASK
0 · Reply
UltimateTrader_22
UltimateTrader_22 Jun. 30 at 11:52 AM
$AIMN AimwellBio's live signal intelligence engine is now tracking 13 source streams in real time - FDA actions, drug recalls, clinical trials, patent filings, global outbreaks, and regulatory divergence. It's running right now. The only question is whether you're seeing what it sees. https://accessnewswire.com/newsroom/en/business-and-professional-services/while-you-were-in-that-meeting-14-signals-moved.-your-competitor-1164121 @AimwellBIO @AimwellPartners
0 · Reply
PrnceMichael
PrnceMichael Jun. 29 at 7:43 PM
$AIMN @AimwellPartners enters the $100B+ RegTech market with the launch of AimwellBio. As healthcare becomes the fastest-growing vertical in regulatory tech, Aimwell is building the "trust layer" for AI in medicine. 🔹 Solving the 47% AI error rate in medical advice. 🔹 Targeting $140B in annual BioPharma intelligence spend. 🔹 Launching the Federated Health Intelligence Network (FHIN). Check out the full release: https://accessnewswire.com/newsroom/en/business-and-professional-services/aimwellbio-launches-the-system-that-catches-what-ai-gets-wrong-b-1157560 #Investing #StockMarket #OTC #AI #BioPharma $AIMN #AimwellBio
0 · Reply
URocka
URocka Jun. 29 at 2:46 PM
$AIMN guess the press release didn't go over well....gonna wait till over $857 a share to break even... that reverse splitting was Devastating for the remaining shareholders...
0 · Reply
Stockprofiler
Stockprofiler Jun. 29 at 2:17 PM
$AIMN AimwellBio's live signal intelligence engine is now tracking 13 source streams in real time - FDA actions, drug recalls, clinical trials, patent filings, global outbreaks, and regulatory divergence. It's running right now. The only question is whether you're seeing what it sees. https://www.accessnewswire.com/newsroom/en/business-and-professional-services/while-you-were-in-that-meeting-14-signals-moved.-your-competitor-1164121 @AimwellBIO @AimwellPartners
0 · Reply
St0ckman691
St0ckman691 Jun. 29 at 1:23 PM
$AIMN news! https://www.newswire.com/news/aimwellbio-continues-onboarding-healthcare-professionals-to-its-verified
0 · Reply
St0ckman691
St0ckman691 Jun. 29 at 1:21 PM
$AIMN was getting accumulated to end last week. Excited to see if we start the week with a bang
1 · Reply
Stockprofiler
Stockprofiler Jun. 29 at 12:51 PM
$AIMN News: @AimwellBio Continues Onboarding Healthcare Professionals to Its Verified Observer Network, Adds One-Click LinkedIn Signup https://www.newswire.com/news/aimwellbio-continues-onboarding-healthcare-professionals-to-its-verified
0 · Reply
PrnceMichael
PrnceMichael Jun. 29 at 11:31 AM
$AIMN #solidsharestructure #lowFloat AimwellBio Reports Strong Early Demand From Hospital Systems and Researchers as FHIN Founding Cohort Takes Shape https://finance.yahoo.com/sectors/healthcare/articles/aimwellbio-reports-strong-early-demand-123000432.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
0 · Reply
maxpax161
maxpax161 Jun. 27 at 9:01 PM
$AIMN after the splits, restructuring and new name/focus this has a chance to have some upside. Reduced share count, and minimal valuation.
0 · Reply
PrnceMichael
PrnceMichael Jun. 26 at 5:53 PM
$AIMN .011 +57.14% One Month Performance +144.44% #Bullish
0 · Reply
Stockprofiler
Stockprofiler Jun. 26 at 5:06 PM
$AIMN Aimwell Bio Expands FHIN Deployment Across U.S. and Australia as Clinical Leaders Move to Replace Unverified AI Hospitalists and Physician Groups Drive Demand for Source-Traceable Intelligence Infrastructure https://finance.yahoo.com/sectors/healthcare/articles/aimwell-bio-expands-fhin-deployment-123000659.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr @AimwellPartners @AimwellBIO #NEWS
0 · Reply